[REVISION HISTORY]

Expanded therapeutic research on metformin and semaglutide

Updated 15 times since CLSTR started tracking revisions of this situation.

What changed

2026-09-09 10:37 UTC → 2026-09-09 23:11 UTC · added ~~removed~~

Recent medical research has identified expanded therapeutic potential for diabetes and obesity medications, specifically metformin and semaglutide, regarding brain health, organ function, and aging. Studies from Baylor College of Medicine suggest metformin may regulate blood sugar by acting directly on the brain. Clinical research into semaglutide has increasingly highlighted anti-aging and protective benefits. A trial at the University of California, San Diego, showed semaglutide slowed molecular markers of aging, while data presented at the European Society of Cardiology congress suggests these GLP-1 receptor agonists may reduce risks for heart attacks, Alzheimer’s, and cancer. Professor Harlan Krumholz of the Yale School of Medicine noted the medications appear to have “far-reaching effects.” Regarding organ health, a meta-analysis in Medicine found semaglutide more than doubled the likelihood of resolving metabolic dysfunction-associated steatohepatitis (MASH). Newer findings also suggest psychiatric and addiction-related benefits, including a 22% reduction in the risk of psychiatric hospitalization for those with bipolar disorder. Research published in Nature supported longevity benefits, finding semaglutide treatment in mice increased median lifespan by approximately 12 percent. Observational data presented at the European Respiratory Society Congress suggests semaglutide is associated with a nearly 40 per cent reduction in asthma attacks and a 20 per cent reduction in COPD flare-ups. Researchers from Imperial College London utilized UK electronic medical records to find significant improvements in airway disease outcomes compared to sulfonylureas. ~~Regarding addiction, while~~ Newer findings also suggest psychiatric and addiction-related benefits, including a 22% reduction in the risk of psychiatric hospitalization for those with bipolar disorder. While an experimental study in the American Journal of Psychiatry found semaglutide did not reduce overall alcohol cravings, it significantly decreased heavy drinking days. Clinicians and patients have also noted a decreased desire for nicotine and other ~~substances, sometimes linked to alcohol causing nausea or uncomfortable fullness. Recent developments also note that in~~ substances. In Brazil, Anvisa has approved generic liraglutide to increase competition and lower costs. However, medical professionals warn that rapid weight loss can lead to side effects such as muscle mass loss and skin sagging.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.